Exosome-based bone-targeting drug delivery alleviates impaired osteoblastic bone formation and bone loss in inflammatory bowel diseases

Guo, Jiawei; Wang, Fuxiao; Yan, Hu; Luo, Ying; Wei, Yan; Xu, Ke; Zhang, Hao; Liu, Han; Bo, Lumin; Lv, Shunli; Sheng, Shihao; Xinchen, Zhuang; Zhang, Tao; Xu, Cuilian; Chen, Xiao; Su, Jiacan

doi:10.1016/j.xcrm.2022.100881

Cited by 61 publications

(47 citation statements)

References 79 publications

(93 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Royo et al reported that changes made to the sialic residues from glycoproteins produced targeted exosomes for specific organs [ 117 ]. Guo et al developed targeted exosomes for bone tissue by the insertion of Golgi glycoprotein 1 into the exosome membrane [ 118 ]. The glycoprotein carried Wnt agonist 1, which reportedly reduced bone loss, accelerated fracture healing in colitis, and increased bone formation in mice [ 118 ].…”

Section: Exosomal Drug Delivery: Solutionsmentioning

confidence: 99%

“…Guo et al developed targeted exosomes for bone tissue by the insertion of Golgi glycoprotein 1 into the exosome membrane [ 118 ]. The glycoprotein carried Wnt agonist 1, which reportedly reduced bone loss, accelerated fracture healing in colitis, and increased bone formation in mice [ 118 ]. Moreover, the presence of negatively charged phospholipids on exosomes increased their clearance through macrophages.…”

Section: Exosomal Drug Delivery: Solutionsmentioning

confidence: 99%

See 1 more Smart Citation

Endogenous Lipid Carriers—Bench-to-Bedside Roadblocks in Production and Drug Loading of Exosomes

Richards

Patel

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

Exosomes are cell-derived, nano-sized extracellular vesicles comprising a lipid bilayer membrane that encapsulates several biological components, such as nucleic acids, lipids, and proteins. The role of exosomes in cell–cell communication and cargo transport has made them promising candidates in drug delivery for an array of diseases. Despite several research and review papers describing the salient features of exosomes as nanocarriers for drug delivery, there are no FDA-approved commercial therapeutics based on exosomes. Several fundamental challenges, such as the large-scale production and reproducibility of batches, have hindered the bench-to-bedside translation of exosomes. In fact, compatibility and poor drug loading sabotage the possibility of delivering several drug molecules. This review provides an overview of the challenges and summarizes the potential solutions/approaches to facilitate the clinical development of exosomal nanocarriers.

show abstract

Section: Exosomal Drug Delivery: Solutionsmentioning

confidence: 99%

Section: Exosomal Drug Delivery: Solutionsmentioning

confidence: 99%

Endogenous Lipid Carriers—Bench-to-Bedside Roadblocks in Production and Drug Loading of Exosomes

Richards

Patel

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…Patients with inflammatory bowel diseases, mainly ulcerative colitis and Crohn's disease, exhibit bone loss and fracture risk due to immunosuppressive treatment, malabsorption, and systemic inflammation. Using established ulcerative colitis and Crohn's disease mouse models, Guo et al 10 investigated bone-marrow-derived stem cells (BMSCs) and tested the delivery of Wnt agonist 1 to BMSCs via Golgi glycoprotein 1 exosome-nanoparticles (GLG1-NPs), to mitigate inflammatory bowel disease-induced bone loss. Both ulcerative colitis and Crohn's disease models demonstrated a considerably compromised bone phenotype, upregulation of inflammatory cytokines, and suppression of the osteogenic Wnt/b-catenin pathway.…”

Section: Conditions Involving Bone Loss and Fracture Riskmentioning

confidence: 99%

What’s New in Musculoskeletal Basic Science

Gugala

2023

Journal of Bone and Joint Surgery

View full text Add to dashboard Cite

“…Над повышением эффективности и безопасности антирезорбтивной терапии ОП и усовершенствованием методов фармакологической коррекции нарушений костного обмена при ОП работают ведущие научные школы как в России, так и за рубежом. В последние годы были открыты и проходят клинические испытания несколько новых молекул и методов лечения ОП, об эффективности и безопасности которых говорить пока рано [8][9][10][11][12][13]. Кроме того, накапливаются данные о клинических особенностях и отдаленных результатах применения давно известных препаратов при длительном ведении больных ОП [14,15].…”

Section: Introductionunclassified

Advantages of zoledronic acid in the therapy of osteoporosis in real clinical practice

Sivordova¹,

Polyakova²,

Papichev³

et al. 2023

Medicinskij sovet

View full text Add to dashboard Cite

Introduction. The development of osteoporosis (OP) increases healthcare costs and often leads to disability of patients. In this regard, the search for ways to improve the effectiveness of OP treatment is very relevant. Today, there is a wide range of drugs for the effective correction of bone metabolism. However, low patient compliance in real clinical practice significantly reduces the effectiveness of therapy.Aim. To study the effect of patient compliance on the effectiveness of Zoledronic acid and Denosumab in OP in real clinical practice.Materials and methods. Study design: a retrospective analysis of outpatient records of 300 patients with OP, who were prescribed Zoledronic acid or Denosumab in 2019, with a prospective analysis of adherence to therapy for 3 years.Results. It was revealed that 12% of patients did not start pathogenetic therapy for OP (control group). 88% (264 patients) started pathogenetic therapy: of these, 22.33% (67 patients) preferred therapy with Denosumab; 65.67% (197 patients) – Zoledronic acid. After 1 year, therapy with Denosumab 19.4%, Zoledronic acid – 19.29% was discontinued. More than 1 month late with the next injection of the drug: Denosumab – 25.37%, Zoledronic acid – 16.24% of patients. Only 55.22% who received Denosumab and 64.47% who received Zoledronic acid fully complied with the recommendations. Most often, a violation of the schedule of drug administration was observed in patients over 75 years of age, alone, with impaired cognitive status. Discontinuation of therapy with Denosumab or violation of the schedule of its administration led to an increase in the level of bone resorption (C-telopeptide type I collagen (CTX-1)). During therapy with Zoledronic acid, there was no increase in CTX-1. In addition, the cost of course treatment with Zoledronic acid is 2–3 times less than with Denosumab.Conclusion. In real clinical practice, zoledronic acid has clinical and pharmacoeconomic advantages, especially in patients with expected low adherence to OP therapy.

show abstract

Exosome-based bone-targeting drug delivery alleviates impaired osteoblastic bone formation and bone loss in inflammatory bowel diseases

Cited by 61 publications

References 79 publications

Endogenous Lipid Carriers—Bench-to-Bedside Roadblocks in Production and Drug Loading of Exosomes

Endogenous Lipid Carriers—Bench-to-Bedside Roadblocks in Production and Drug Loading of Exosomes

What’s New in Musculoskeletal Basic Science

Advantages of zoledronic acid in the therapy of osteoporosis in real clinical practice

Contact Info

Product

Resources

About